Day One Biopharmaceuticals

Day One Biopharmaceuticals is a clinical-stage biotechnology company dedicated to developing targeted cancer therapies for patients of all ages, with a particular emphasis on pediatric patients who have historically been underserved in cancer treatment advancements. The company is committed to addressing the unique needs of children and adults facing cancer by creating therapies that are informed by the biology of childhood cancers. Day One Biopharmaceuticals aims to bring promising treatments rapidly to market, focusing on those that can benefit both younger and older patients. The company's lead product candidate, DAY101, is an oral, brain-penetrant pan-RAF kinase inhibitor designed to target genetically defined cancers. By licensing and acquiring innovative products from research institutions and other biopharmaceutical companies, Day One Biopharmaceuticals seeks to provide effective treatment options for families confronted with the challenges of a cancer diagnosis.